Abstract
The objective of this study was to develop a population pharmacokinetic model for rifampin in elephants. Rifampin concentration data from three sources were pooled to provide a total of 233 oral concentrations from 37 Asian elephants. The population pharmacokinetic models were created using Monolix (version 4.2). Simulations were conducted using ModelRisk. We examined the influence of age, food, sex, and weight as model covariates. We further optimized the dosing of rifampin based upon simulations using the population pharmacokinetic model. Rifampin pharmacokinetics were best described by a one-compartment open model including first-order absorption with a lag time and first-order elimination. Body weight was a significant covariate for volume of distribution, and food intake was a significant covariate for lag time. The median C-max of 6.07g/mL was below the target range of 8-24g/mL. Monte Carlo simulations predicted the highest treatable MIC of 0.25g/mL with the current initial dosing recommendation of 10mg/kg, based upon a previously published target AUC(0-24)/MIC>271 (fAUC>41). Simulations from the population model indicate that the current dose of 10mg/kg may be adequate for MICs up to 0.25g/mL. While the targeted AUC/MIC may be adequate for most MICs, the median C-max for all elephants is below the human and elephant targeted ranges.